Mesangial cell biology

Experimental Cell Research

Volumn 318, Issue 9, 2012, Pages 979-985

  Abboud, Hanna E ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Diabetes; Fibrosis; Kidney; Mesangial cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE; AMINO ACID; ANGIOGENESIS INHIBITOR; ANGIOTENSIN II; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 4; CHEMOKINE; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SEROTONIN; SMAD1 PROTEIN; STAT PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UPSTREAM STIMULATORY FACTOR 1; UPSTREAM STIMULATORY FACTOR 2; VASCULOTROPIN A; WNT PROTEIN;

APOPTOSIS; CELL CULTURE; CELL DAMAGE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL ISOLATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CYTOKINE PRODUCTION; CYTOLOGY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG TARGETING; EX VIVO STUDY; GENE EXPRESSION; GENETIC MANIPULATION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY DISEASE; MEDIATOR; MESANGIUM CELL; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 84859844692     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.025     Document Type: Review

References (59)

1. Schlöndorff D., Banas B. The mesangial cell revisited: no cell is an island. J. Am. Soc. Nephrol. 2009, 20:1179-1187.
2. Qian Y., Feldman E., Pennathur S., Kretzler M., Brosius F.C. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008, 57:1439-1445.
3. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., Chugh S., Danesh F.R. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. 2008, 233:4-11.
4. Simonson M.S. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int. 2007, 71:846-854.
5. Scindia Y.M., Deshmukh U.S., Bagavant H. Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv. Drug Deliv. Rev. 2010, 62:1337-1343.
6. Ma R., Pluznick J.L., Sansom S.C. Ion channels in mesangial cells: function, malfunction, or fiction. Physiology 2005, 20:102-111.
7. Quaggin S.E., Kreidberg J.A. Development of the renal glomerulus: good neighbors and good fences. Development 2008, 135:609-620.
8. Vaughan M.R., Quaggin S.E. How do mesangial and endothelial cells form the glomerular tuft?. J. Am. Soc. Nephrol. 2008, 19:24-33.
9. Watson S., Cailhier J.F., Hughes J., Savill J. Apoptosis and glomerulonephritis. Curr. Dir. Autoimmun. 2006, 9:188-204.
10. Simonson M., Ismail-Beigi F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J. Biol. Chem. 2011, 286:11003-11008.
11. Tanaka M., Asada M., Higashi A.Y., Nakamura J., Oguchi A., Tomita M., Yamada S., Asada N., Takase M., Okuda T., Kawachi H., Economides A.N., Robertson E., Takahashi S., Sakurai T., Goldschmeding R., Muso E., Fukatsu A., Kita T., Yanagita M. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J. Clin. Invest. 2010, 120:768-777.
12. Keeling J., Herrera G. Human matrix metalloproteinases: characteristics and pathologic role in altering mesangial homeostasis. Microsc. Res. Tech. 2008, 71:371-379.
13. Striker G.E. The aging kidney phenotype and systemically derived stem cells. J. Am. Soc. Nephrol. 2011, 22:1958-1960.
14. Alique M., Calleros L., Luengo A., Griera M., Iñiguez M.Á., Punzón C., Fresno M., Rodríguez-Puyol M., Rodríguez-Puyol D. Changes in extracellular matrix composition regulate cyclooxygenase-2 expression in human mesangial cells. Am. J. Physiol. Cell Physiol. 2011, 300:C907-C918.
15. Floege J., Eitner F., Alpers C.E. A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 2008, 19:12-23.
16. Maeshima Y. Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells. Clin. Exp. Nephrol. 2005, 9:271-281.
17. Cheng J., Grande J.P. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp. Biol. Med. 2007, 232:38-51.
18. Yuan P., Xue H., Zhou L., Qu L., Li C., Wang Z., Ni J., Yu C., Yao T., Huang Y., Wang R., Lu L. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrol. Dial. Transplant. 2011, 26:2119-2126.
19. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006, 69:213-217.
20. Jefferson J.A., Shankland S.J., Pichler R.H. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008, 74:22-36.
21. Masson E., Lagarde M., Wiernsperger N., El Bawab S. Hyperglycemia and glucosamine-induced mesangial cell cycle arrest and hypertrophy: common or independent mechanisms?. IUBMB Life 2006, 58:381-388.
22. Gnudi L., Thomas S.M., Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J. Am. Soc. Nephrol. 2007, 18:2226-2232.
23. Daroux M., Prévost G., Maillard-Lefebvre H., Gaxatte C., D'Agati V., Schmidt A., Boulanger E. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 2010, 36:1-10.
24. Schena F., Gesualdo L. Pathogenic mechanisms of diabetic nephropthy. J. Am. Soc. Nephrol. 2005, (Suppl. 1):S30-S33.
25. Sanchez-Niño M.D., Benito-Martin A., Ortiz A. New paradigms in cell death in human diabetic nephropathy. Kidney Int. 2010, 78:737-744.
26. Marrero M., Banes-Bercell A., Stern D., Eaton D. Role of the JAK/STAT signaling pathways in diabetic nephropathy. Am. J. Physiol. 2006, 290:F762-F768.
27. Abe H., Matsubara T., Arai H., Doi T. Role of Smad1 in diabetic nephropathy: molecular mechanisms and implications as a diagnostic marker. Histol. Histopathol. 2011, 26:531-541.
28. Haase V.H. The sweet side of HIF. Kidney Int. 2010, 78:10-13.
29. Kishi S., Abe H., Akiyama H., Tominaga T., Murakami T., Mima A., Nagai K., Kishi F., Matsuura J., Matsubara T., Iehara N., Ueda O., Fukushima N., Jishage K., Doi T. SOX9 protein induces a chondrogenic phenotype of mesangial cells and contributes to advanced diabetic nephropathy. J. Biol. Chem. 2011, 286:32162-32169.
30. Wiggins J., Patel S., Shedden K., Goyal M., Wharram B., Martini S., Kretzler M., Wiggins R. NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J. Am. Soc. Nephrol. 2010, 21:587-597.
31. Lin C., Wang J., Ko J., Huang Y., Kuo Y., Wang F. Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J. Am. Soc. Nephrol. 2010, 21:124-135.
32. Sato A.Y., Antonioli E., Tambellini R., Campos A.H. ID1 inhibits USF2 and blocks TGF-β-induced apoptosis in mesangial cells. Am. J. Physiol. Renal Physiol. 2011, 301:F1260-F1269.
33. Uttarwar L., Gao B., Ingram A.J., Krepinsky J.C. SREBP-1 activation by glucose mediates TGF-β upregulation in mesangial cells. Am. J. Physiol. Renal Physiol. 2012, 302:F329-F341.
34. Tominaga T., Abe H., Ueda O., Goto C., Nakahara K., Murakami T., Matsubara T., Mima A., Nagai K., Araoka T., Kishi S., Fukushima N., Jishage K., Doi T. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J. Biol. Chem. 2011, 286:20109-20116.
35. Zhang Q., Shi Y., Wada J., Malakauskas S., Liu M., Ren Y., Du C., Duan H., Li Y., Li Y., Zhang Y. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS One 2010, 5:e11709.
36. Lappin D., McMahon R., Murphy M., Brady H. Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy. Nephrol. Dial. Transplant. 2002, 17:65-67.
37. Ortiz-Muñoz G., Lopez-Parra V., Lopez-Franco O., Fernandez-Vizarra P., Mallavia B., Flores C., Sanz A., Blanco J., Mezzano S., Ortiz A., Egido J., Gomez-Guerrero C. Suppressors of cytokine signaling abrogate diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:763-772.
38. Mishra R., Cool B., Laderoute K., Foretz M., Viollet B., Simonson M. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J. Biol. Chem. 2008, 283:10461-10469.
39. Sanchez A.P., Zhao J., You Y., Declèves A.E., Diamond-Stanic M., Sharma K. Role of the USF1 transcription factor in diabetic kidney disease. Am. J. Physiol. Renal. Physiol. 2011, 301:F271-F279.
40. Kume S., Thomas M.C., Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012, 61:23-29.
41. Buller C.L., Heilig C.W., Brosius F.C. GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Am. J. Physiol. Renal Physiol. 2011, 301:F588-F596.
42. Liu L., Hu X., Cai G.Y., Lv Y., Zhuo L., Gao J.J., Cui S.Y., Feng Z., Fu B., Chen X.M. High glucose-induced hypertrophy of mesangial cells is reversed by connexin43 overexpression via PTEN/Akt/mTOR signaling. Nephrol. Dial. Transplant. 2012, 27:90-100.
43. Osman B., Doller A. el-S. Akool, M. Holdener, E. Hintermann, J. Pfeilschifter, W. Eberhardt, Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell. Signal. 2009, 21:1806-1817.
44. Forbes J., Coughlan M., Cooper M. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
45. S. Hagiwara, P. Kantharidis, M. Cooper, What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition? Curr Hypertens Rep. (in press) (Electronic publication ahead of print).
46. Kitada M., Kume S., Imaizumi N., Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011, 60:634-643.
47. Shi Y., Ren Y., Zhao L., Du C., Wang Y., Zhang Y., Li Y., Zhao S., Duan H. Knockdown of thioredoxin interacting protein attenuates high glucose-induced apoptosis and activation of ASK1 in mouse mesangial cells. FEBS Lett. 2011, 585:1789-1795.
48. Gorin Y., Block K., Hernandez J., Bhandari B., Wagner B., Barnes J., Abboud H. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem. 2005, 280:39616-39626.
49. Block K., Gorin Y., Abboud H. Subcellular localization of Nox4 and regulation in diabetes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14385-14390.
50. Kim K.M., Kim Y.S., Jung D.H., Lee J., Kim J.S. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose. Exp. Cell Res. 2012, 318:152-159.
51. Zheng H., Whitman S.A., Wu W., Wondrak G.T., Wong P.K., Fang D., Zhang D.D. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60:3055-3066.
52. Li H., Wang F., Zhang L., Cao Y., Liu W., Hao J., Liu Q., Duan H. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell. Signal. 2011, 23:1625-1632.
53. Chacko B.K., Reily C., Srivastava A., Johnson M.S., Ye Y., Ulasova E., Agarwal A., Zinn K.R., Murphy M.P., Kalyanaraman B., Darley-Usmar V. Prevention of diabetic nephropathy in Ins2(+/)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem. J. 2010, 432:9-19.
54. Graham S., Yuan J.P., Ma R. Canonical transient receptor potential channels in diabetes. Exp. Biol. Med. (Maywood) 2012, 237:111-118.
55. Choi C.H., Zuckerman J.E., Webster P., Davis M.E. Targeting kidney mesangium by nanoparticles of defined size. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6656-6661.
56. Pujalté I., Passagne I., Brouillaud B., Tréguer M., Durand E., Ohayon-Courtès C., L'Azou B. Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells. Part Fibre. Toxicol. 2011, 8:10.
57. Ichinose K., Rauen T., Juang Y., Kis-Toth K., Mizui M., Koga T., Tsokos G. Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 2011, 187:5500-5504.
58. Ghayur M., Krepinsky J., Janssen L. Contractibility of the renal glomerulus and mesangial cells: lingering doubts and strategies for the future. Med. Hypotheses Res. 2008, 4:1-9.
59. Aben J., Hoogervorst D., Paul L., Borrias M., Noble N., Border W., Bruijn J., de Heer E. Genes expressed by the kidney, but not by bone marrow-derived cells, underlie the genetic predisposition to progressive glomerulosclerosis after mesangial injury. J. Am. Soc. Nephrol. 2003, 14:2264-2270.